The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually
updated evidence-based strategy for asthma management and prevention, which can be …

The 2020 Focused Updates to the Asthma Management Guidelines: A Report from the
National Asthma Education and Prevention Program Coordinating Committee Expert Panel …

Background As asthma symptoms worsen, patients typically rely on short-acting β2-agonist
(SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves …

Background In patients with mild asthma, as-needed use of an inhaled glucocorticoid plus a
fast-acting β2-agonist may be an alternative to conventional treatment strategies. Methods …

Executive summary Asthma is responsible for considerable global morbidity and health-care
costs. Substantial progress was made against key outcomes such as hospital admissions …

Background Patients with mild asthma often rely on inhaled short-acting β2-agonists for
symptom relief and have poor adherence to maintenance therapy. Another approach might …

GINA no longer recommends treating adults/adolescents with asthma with short-acting
bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a …

Background In double-blind, placebo-controlled trials, budesonide–formoterol used on an
as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed …

Background In adults with mild asthma, a combination of an inhaled corticosteroid with a fast-
onset long-acting β-agonist (LABA) used as reliever monotherapy reduces severe …

Background Although small airway disease is a feature of asthma, its association with
relevant asthma outcomes remains unclear. The ATLANTIS study was designed to identify …